Wall Street Zen Upgrades Citius Pharmaceuticals (NASDAQ:CTXR) to Hold

Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

CTXR has been the topic of several other reports. D. Boral Capital reiterated a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research report on Thursday, December 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

Citius Pharmaceuticals Price Performance

CTXR opened at $0.84 on Friday. Citius Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $5.95. The stock has a market cap of $17.46 million, a P/E ratio of -0.25 and a beta of 1.51. The stock’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.32.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CTXR. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the second quarter valued at $40,000. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals during the second quarter worth approximately $32,000. Finally, Arkadios Wealth Advisors increased its position in Citius Pharmaceuticals by 100.0% during the second quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock worth $32,000 after purchasing an additional 10,000 shares during the last quarter. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.